Trent J. Volz, Ph.D. - Publications

Affiliations: 
2005 Washington State University, Pullman, WA, United States 
Area:
Analytical Chemistry, Biochemistry

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2009 Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE. Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue. Journal of Neuroscience Methods. 180: 317-20. PMID 19464519 DOI: 10.1016/j.jneumeth.2009.03.015  0.4
2009 Farnsworth SJ, Volz TJ, Hanson GR, Fleckenstein AE. Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation. The Journal of Pharmacology and Experimental Therapeutics. 328: 807-12. PMID 19038779 DOI: 10.1124/jpet.108.146159  0.4
2009 Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse (New York, N.Y.). 63: 147-51. PMID 19021208 DOI: 10.1002/syn.20580  0.4
2009 Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE. Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles. Journal of Neuroscience Methods. 177: 177-82. PMID 18992277 DOI: 10.1016/j.jneumeth.2008.10.004  0.4
2009 Fleckenstein AE, Volz TJ, Hanson GR. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology. 56: 133-8. PMID 18662707 DOI: 10.1016/j.neuropharm.2008.07.002  0.4
2008 Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity. Annals of the New York Academy of Sciences. 1139: 285-90. PMID 18991873 DOI: 10.1196/annals.1432.012  0.4
2008 Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors. The Journal of Pharmacology and Experimental Therapeutics. 327: 161-7. PMID 18591219 DOI: 10.1124/jpet.108.139386  0.4
2007 Volz TJ, Farnsworth SJ, King JL, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. The Journal of Pharmacology and Experimental Therapeutics. 323: 738-45. PMID 17693585 DOI: 10.1124/jpet.107.126888  0.4
2007 Volz TJ, Fleckenstein AE, Hanson GR. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment. Addiction (Abingdon, England). 102: 44-8. PMID 17493052 DOI: 10.1111/j.1360-0443.2007.01771.x  0.4
2007 Bjorklund NL, Volz TJ, Schenk JO. Differential effects of Zn2+ on the kinetics and cocaine inhibition of dopamine transport by the human and rat dopamine transporters. European Journal of Pharmacology. 565: 17-25. PMID 17408612 DOI: 10.1016/j.ejphar.2007.02.027  1
2007 Volz TJ, Hanson GR, Fleckenstein AE. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. Journal of Neurochemistry. 101: 883-8. PMID 17250674 DOI: 10.1111/j.1471-4159.2006.04419.x  0.4
2007 Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annual Review of Pharmacology and Toxicology. 47: 681-98. PMID 17209801 DOI: 10.1146/annurev.pharmtox.47.120505.105140  0.4
2006 Volz TJ, Hanson GR, Fleckenstein AE. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function. Synapse (New York, N.Y.). 60: 474-7. PMID 16897727 DOI: 10.1002/syn.20321  0.4
2006 Rau KS, Birdsall E, Volz TJ, Riordan JA, Baucum AJ, Adair BP, Bitter R, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake. The Journal of Pharmacology and Experimental Therapeutics. 318: 676-82. PMID 16687477 DOI: 10.1124/jpet.105.099200  0.4
2006 Volz TJ, Hanson GR, Fleckenstein AE. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. Journal of Neuroscience Methods. 155: 109-15. PMID 16480775 DOI: 10.1016/j.jneumeth.2006.01.002  0.4
2005 Volz TJ, Schenk JO. A comprehensive atlas of the topography of functional groups of the dopamine transporter. Synapse (New York, N.Y.). 58: 72-94. PMID 16088952 DOI: 10.1002/syn.20183  1
2005 Volz TJ, Bjorklund NL, Schenk JO. Methylphenidate analogs with behavioral differences interact differently with arginine residues on the dopamine transporter in rat striatum. Synapse (New York, N.Y.). 57: 175-8. PMID 15945061 DOI: 10.1002/syn.20161  1
2005 Robinson DL, Volz TJ, Schenk JO, Wightman RM. Acute ethanol decreases dopamine transporter velocity in rat striatum: in vivo and in vitro electrochemical measurements. Alcoholism, Clinical and Experimental Research. 29: 746-55. PMID 15897718 DOI: 10.1097/01.ALC.0000164362.21484.14  0.4
2004 Volz TJ, Schenk JO. L-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism. Synapse (New York, N.Y.). 54: 173-82. PMID 15452864 DOI: 10.1002/syn.20075  1
2004 Volz TJ, Kim M, Schenk JO. Covalent and noncovalent chemical modifications of arginine residues decrease dopamine transporter activity. Synapse (New York, N.Y.). 52: 272-82. PMID 15103693 DOI: 10.1002/syn.20021  1
Show low-probability matches.